Costs by Site of Service for Commercially-Insured Patients with Metastatic Pancreatic Cancer Receiving Guideline-Recommended Chemotherapy: Comparing Community Oncology and Hospital Outpatient Settings
Open Access
- 10 October 2022
- journal article
- research article
- Published by Taylor & Francis Ltd in ClinicoEconomics and Outcomes Research
- Vol. ume 14, 653-663
- https://doi.org/10.2147/ceor.s373316
Abstract
Purpose: Compare total cost of care (TCOC) for commercially-insured patients with metastatic pancreatic cancer receiving FDA-approved/NCCN Category 1 preferred regimens in community oncology or hospital outpatient settings. Patients and Methods: We used the 2016– 2019 MarketScan® and Milliman Consolidated Health Cost Guidelines Sources Database (CHSD) administrative claims data to compare utilization of healthcare services and expenditures for commercially-insured patients receiving chemotherapy in community oncology or hospital outpatient settings. We identified patients with metastatic pancreatic cancer using ICD-10 diagnosis codes in 2016– 2019 MarketScan® and Milliman Consolidated Health Cost Guidelines Sources Database files. Patients were assigned to cohorts based on where they received the plurality of chemotherapy services: community oncology or hospital outpatient settings. Total cost of care (TCOC) and healthcare resource utilization metrics were calculated per line of therapy (LOT) for patients receiving similar chemotherapy regimens in each cohort, and differences between cohorts were evaluated using t-testing and chi-squared statistical methods. Results: Although cohorts had similar demographics, chemotherapy regimen use, and length of therapy, the mean TCOC among all patients receiving chemotherapy in hospital outpatient settings was 41% higher compared to community oncology settings. Median TCOC was 35% higher in hospital outpatient settings than in community oncology settings. Mean admissions and readmissions per beneficiary were 7% and 16% higher, respectively, for thse treated in hospital outpatient versus community oncology settings. We observed no differences in the use of emergency department or hospice care between the cohorts. Conclusion: Our study indicates that patients receiving chemotherapy at community oncology centers are associated with better or equivalent outcomes and lower costs than patients receiving the same regimen in a hospital outpatient setting.Keywords
This publication has 15 references indexed in Scilit:
- What Are the Potential Savings From Steering Patients to Lower-Priced Providers? A Static Analysis2019
- Charlson Comorbidity Index: ICD-9 Update and ICD-10 Translation2019
- The harmonic mean p -value for combining dependent testsProceedings of the National Academy of Sciences of the United States of America, 2019
- Spending by Commercial Insurers on Chemotherapy Based on Site of Care, 2004-2014JAMA Oncology, 2018
- Consequences of the 340B Drug Pricing ProgramThe New England Journal of Medicine, 2018
- Cancer statistics, 2018CA: A Cancer Journal for Clinicians, 2018
- Current status on the place of FOLFIRINOX in metastatic pancreatic cancer and future directionsTherapeutic Advances in Gastroenterology, 2017
- National estimates of price variation by site of care.2016
- Systemic therapy in stage IV pancreatic cancer: a population-based analysis using the National Cancer Data BaseTherapeutic Advances in Medical Oncology, 2015
- Cost differential by site of service for cancer patients receiving chemotherapy.2015